Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Vera Health

Vera Health, which says more than 800,000 clinicians use its free search tool, raises $28.5M

Threshold Ventures led the Series A for the 12-person San Francisco company, which grades medical evidence behind each answer. The product is free to clinicians, and the release does not say how Vera makes money.

Charted Staff2 min read
From a company announcement published Oct. 27, 2026
The main reading room of the National Library of Medicine in 2008.
The main reading room of the National Library of Medicine in 2008. File photo.Sage Ross / Wikimedia Commons (CC BY-SA 3.0)
Amount
$28.5M
Type
Series A
Company
Vera Health
Lead investor
Threshold Ventures
Sector
Health AI
Announced
Oct. 27, 2026

Vera Health says its user base has grown from a few thousand clinicians a year ago to more than 800,000, most of whom heard about it from a colleague. The company has 12 employees.

The San Francisco company said Oct. 27 that it raised $28.5 million in a Series A round led by Threshold Ventures. Mantis VC and SV Angel joined, and existing investors Y Combinator and Gradient added to their stakes, lifting its total raised to $32 million. It did not disclose a valuation.

Why it matters: Vera measures itself against OpenEvidence and Doximity, both of which it named in its announcement, with a tiny team and a free product. The release does not say how the company makes money or plans to.

Vera said its app drew more downloads in September than OpenEvidence and Doximity put together, and that it has ranked first among clinical apps for worldwide downloads on Apple's and Google's app stores every month since June, citing download data from Appark.

How it works

Vera calls its product an AI search engine for clinicians that finds and grades evidence before it writes an answer. The company said it searches over 60 million peer-reviewed papers plus drug labels, guidelines and consensus statements, and weighs each source on study design, cohort size, how recent it is, journal quality, citation impact and level of evidence.

Each claim in an answer links to the research behind it and is color-coded by how strong that evidence is, including red when the support is thin, the company said.

"Unlike other tools, we believe there's value in making uncertainty visible," Maxime Allouch, a co-founder, said in the announcement. Vera also said it has partnered with the American College of Emergency Physicians to bring ACEP clinical policies into the platform with attribution.

Growth abroad

Vera highlighted its reach in Europe. Citing its own data, the company said roughly a quarter of physicians in Spain and in Italy use the platform, as do about one in seven in France. It said it gives priority to local guidelines while drawing on global research, and a feature called Vera Spaces lets health systems load their own protocols and pathways.

The release also suggests the money arrived months before the announcement. Vera said its daily user count now exceeds the monthly user count it had at the time it raised the Series A.

Taieb Bennani and Maxime Allouch started Vera at Y Combinator in 2024. The company describes them as MIT graduates who are the sons of doctors. "We don't have the biggest team or the most money," Bennani said.

Vera said it will spend the money on its clinical evidence infrastructure, on entering more markets and on closer ties with health systems, publishers and medical societies. It said the tool will remain free to licensed clinicians and to trainees.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.